Daiichi Sankyo To Start Phase III Nimotuzumab Trials In Japan For Gastric, Lung Cancer
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo will start Phase III trials of recombinant humanized IgG1 monoclonal antibody nimotuzumab for treatment of patients with lung squamous cell carcinoma and gastric cancer in Japan.